Kapil Patel - The Informed Second Opinion

Dr. KAPIL N. PATEL, M.D

Dr. Kapil N. Patel is currently the Director, Advanced Lung Disease and Lung Transplant Programs, Pulmonary and Critical Care Medicine, Wake Forest University School of Medicine,Winston-Salem, North Carolina, USA. He is also an Associate Professor, Pulmonary and Critical Care Medicine Wake Forest University School of Medicine.

Email: kapil.patel@advocatehealth.org

Education

Academia Medyczna w Lublinie, 2001 Medical University of Lublin) 08/1997 – 06/2001

Syracuse University School of Arts and Science, Biology, Bachelor of Science 08/1993 – 05/1997

Postgraduate Training

Stanford University Medical Center, 300 Pasteur Drive, Stanford CA 08/2008 – 07/2009

Heart-Lung and Lung Transplant Fellowship

University of Vermont College of Medicine, 111 Colchester Avenue, Burlington, VT 07/2004 – 07/2007

Pulmonary & Critical Care Medicine Fellowship

Monmouth Medical Center (affiliate Drexel University) 300 2^nd Avenue, Long Branch, NJ 07/2001 – 07/2004

Internal Medicine Internship and Residency

American Board of Internal Medicine 2004, 2014

ABIM Pulmonary Medicine 2006, 2016

ABIM Critical Care Medicine 2007, 2018

State of North Carolina Board License (2025-02151) Active

State of Florida Medical Board License (ME 128843) Active

State of California Medical Board License (A 105083) Inactive

State of Maryland Medical Board License (D66342) Inactive

State of New York Medical Board License (242027) Inactive

State of Vermont Medical Board License (042.0010697) Inactive

Awards, Honors, Honorary Society Memberships

Teaching Award, PCCM Stanford 2012

Appointments

Academic

Associate Professor, Pulmonary and Critical Care Medicine, Wake Forest University School of Medicine08/2025 – Present

Associate Professor, Pulmonary and Critical Care Medicine, University of South Florida Morsani College of Medicine 06/2019 – 02/2025

Assistant Professor, Pulmonary and Critical Care Medicine University of South Florida Morsani College of Medicine 06/2016 – 06/2019

Assistant Professor, Pulmonary and Critical Care Medicine, Stanford University School of Medicine 09/2011 – 08/2016

Assistant Professor, Pulmonary and Critical Care Medicine, University of Maryland Medical Center 08/2010 – 08/2011

Clinical Instructor, Pulmonary and Critical Care Medicine, University of Vermont Medical Center 07/2007 – 07/2008

Administrative

Chief of Pulmonary and Critical Care Medicine, Tampa General Hospital 08/2020 – 07/2022

Critical Care Steering Committee Member, Tampa General Hospital 08/2017 – 02/2025

Hospital

Director, Advanced Lung Disease and Lung Transplant Programs, Pulmonary and Critical Care Medicine, Wake Forest University School of Medicine 08/2025 – Present

Director, Center for Advanced Lung Disease and Lung Transplant Program, Pulmonary and Critical Care Medicine, University of South Florida Morsani College of Medicine 08/2016 – 12/2023

Medical Director, Heart-Lung and Lung Transplant University of South Florida Morsani College of Medicine

06/2016 02/2025

Director, VV Extracorporeal Membrane Oxygenation (ECMO) 01/2020 – 12/2023

Director, Cystic Fibrosis Program University of South Florida Morsani College of Medicine 06/2016 – 12/2023 Director, Interstitial Lung Disease Program University of South Florida Morsani College of Medicine 06/2017 – 09/2019 Director, Interstitial Lung Disease Program Stanford University School of Medicine 07/2014 – 08/2016

Other

Attending, Pulmonary and Critical Care Medicine Pulmonary and Critical Care Associates of Baltimore UpperUpper Chesapeake Medical Center 07/2009 – 08/2011

Teaching, Lecture

Stanford University Medical Center

Internal Medicine Residency Training Program:

“Pulmonary Function Test” 2012, 2013, 2014

Pulmonary Critical Care Fellowship Program: PCCM Lecture Series “Interstitial Lung Disease Management”

2014, 2015, 2016

“Lung Transplant Post-Operative Complications” 2014, 2015

“Lung Transplant Management” 2013, 2014

University of South Florida, Morsani College of Medicine

EBCR II CPS II Fall 2023

Extracorporeal Membrane Oxygenator Course Fall 2022

Teaching, Supervisory

Fellow Mentoring

University of South Florida, Morsani College of Medicine - Patrick Fay, MD 2019 - 2020

Stanford University Medical Center - Ritbune Prakobkit, MD 2015 - 2016

Lectures by Invitation

Update on Transplantation. Stanford Cystic Fibrosis Education Day Stanford University Medical Center, Stanford, CA 8/2014

Worsening Disease: Which course to take? Understanding Pulmonary Fibrosis: Seminar for patients, caregivers and families. Coalition for Pulmonary Fibrosis, Stanford University Medical Center, Stanford, CA 3/2015

Non-invasive monitoring of infection and rejection after lung transplantation. International Society for Heart and Lung Transplantation, Nice, France. 4/2015

Surgical Options: Lung transplant and PTE surgery for CTEPH. Pulmonary Hypertension Association (Patient Education Program Associate), Tampa, FL 11/2016

Lung Allocation Score: Development, Implementation and Results. Transplant Grand Rounds at Tampa General Hospital, Tampa, FL. 3/2017

Lung Transplantation for Patients with ILD Transplantation by the Bay, Center for Advanced Medical Learning and Simulation, Tampa, FL 3/2018

Recognizing and Managing Complications and Comorbidities after Lung Transplantation: An Update. American Thoracic Surgery International Conference, San Diego, CA. 5/2018

Lung Transplantation Medicine Grand Rounds, NCH Healthcare System, Naples, FL 10/2023 Navigating the Evaluation Process Pulmonary Fibrosis Foundation Summit Meeting Orlando, FL 11/2023

Stanford Cardiothoracic Transplantation Summit 1 Too Close for Too Long? Need for Remote Monitoring in Thoracic Transplantation Vail, Colorado 1/2024

Scholarly Activity

Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts (CAG-00324R2), Dates: Awarded 10 OCT 2020

Funds earned: non-applicable

Number of patients enrolled and completed: non-applicable pending activation

Funding source: Washington University (Therakos Inc)

Project Number: 61232843

Role: Principal Investigator (Site)

A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Efficacy and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI Investigational eFlow® Device plus Standard of Care versus Standard of Care Alone in the Treatment of Chronic Lung Allograft Dysfunction / Bronchiolitis Obliterans Syndrome in Patients post Single Lung Transplantation (BT-L-CSA-301)

Dates: Pending Activation Awarded: 08JUN2020

Funds earned: non-applicable

Number of patients enrolled and completed: non-applicable

Funding Source: pharmaceutical industry funded

Project Number: 6123829000

Role: PI

A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Efficacy and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI Investigational eFlow® Device plus Standard of Care versus Standard of Care Alone in the Treatment of Chronic Lung Allograft Dysfunction / Bronchiolitis Obliterans Syndrome in Patients post Double Lung Transplantation (BT-L-LSA -302)

Dates: Pending Activation Awarded: 08JUN2020

Funds earned: non-applicable

Number of patients enrolled and completed: non-applicable

Funding Source: pharmaceutical industry funded

Project Number: 6123829100

Role: PI

A Phase III, Multicenter, Open-Label, Extension Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI Investigational eFlow® Device plus Standard of Care in the Treatment of Bronchiolitis Obliterans Syndrome in Patients post Single or Double Lung Transplantation (BT-L-CSA-303-FU)

Dates: Pending Activation Awarded: 08JUN2020

Funds earned: non-applicable

Number of patients enrolled and completed: non-applicable

Funding Source: pharmaceutical industry funded

Project Number: Pending

Role: PI

A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects with Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation

Dates: 05NOV2018-present

Funds earned: to date $134,615.22

Number of patients enrolled and completed: 4 enrolled – study ongoing

Funding Source: pharmaceutical industry funded

Project Number: 6123819800

Role: PI

Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial

Dates: 10OCT2019 – 22OCT2020

Funds earned: $74,280.00

Number of patients enrolled and completed: 4 enrolled completed 0, closed early by sponsor

Funding Source: pharmaceutical industry funded

Project Number: 6123822200

Role: PI

A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older with Cystic Fibrosis. (Vertex101)

Dates: 14NOV2019 - 12OCT2020

Funds earned: $42,209.00

Number of patients enrolled and completed: 2 enrolled, 1 completed

Funding Source: pharmaceutical industry funded

Project Number: 6123822500

Role: PI

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis

Dates: 06DEC2019 – 09NOV2020

Funds earned: $81,238.94

Number of patients enrolled and completed: 5 enrolled, 4 completed

Funding Source: pharmaceutical industry funded

Project Number: 6123818000

Role: PI

A prospective observational study in cystic fibrosis patients with chronic respiratory Pseudomonas aeruginosa infection treated with TOBI® Podhaler™ (tobramycin inhalation powder) or other FDA approved inhaled antipseudomonal antibacterial drugs (Tobi Podhaler)

Dates: 01OCT2016 - ongoing

Funds earned: $9,015.00

Number of patients enrolled and completed: 5 enrolled, 3 completed

Funding Source: pharmaceutical industry funded

Project Number: 6123818500

Role: PI

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects with Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Dates: 30OCT2018 – 22OCT2019

Funds earned: $56,823.50

Number of patients enrolled and completed: 2 enrolled, 2 completed

Funding Source: pharmaceutical industry funded

Project Number: 6123818600

Role: PI

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects with Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F)

Dates: 21SEP2018 – 20FEB2019

Funds earned: $39,502.80

Number of patients enrolled and completed: 2 enrolled, 2 completed

Funding Source: pharmaceutical industry funded

Project Number: 6128319700

Role: PI

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects with Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F) (VX17-445-103)

Dates: 31MAR2020 – 09OCT2020

Funds earned: N/A

Number of patients enrolled and completed: 1 enrolled, 1 completed

Funding Source: pharmaceutical compassionate use

Project Number: N/A

Role: PI

The EPIC Observational Study: Longitudinal Assessment of Risk Factors for and Impact of Pseudomonas aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with CF

Dates: 22MAR2018 – MAR2020

Funds earned: Pending

Number of patients enrolled and completed: 2 enrolled, 2 completed

Funding Source: pharmaceutical industry funded

Project Number: N/A

Role: PI

A Post-approval Observational Study to Evaluate the Long-term Effectiveness and Safety of Orkambi in US Patients Who Completed Study VX12-809-105 Part A

Dates: 06DEC2019 – 12MAR2019

Funds earned: $8,678.00

Number of patients enrolled and completed: 4 enrolled, 4 completed

Funding Source: pharmaceutical industry funded

Project Number: 6123819500

Role: PI

A Study to Evaluate the Safety and Efficacy of Long-Term Treatment With VX-661 in Combination with Ivacaftor in Subjects with Cystic Fibrosis Who Have an F508del-CFTR Mutation (VX14-661-110)

Dates: OCT2016 – JUN2018

Funds earned: $4,350.00

Number of patients enrolled and completed: Pending

Funding Source: pharmaceutical industry funded

Project Number: 6123816400

Role: PI

A Phase 1/2 Study of VX-445 in Healthy Subjects and Subjects with Cystic Fibrosis VX16-445-001

Dates: SEP2017 – DEC2018

Funds earned: $33,474.10

Number of patients enrolled and completed: 8 enrolled, 4 completed

Funding Source: pharmaceutical industry funded

Project Number: 6123816700

Role: PI

Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Efficacy, and Tolerability of Tezacaftor/Ivacaftor (TEZ/IVA) in an Orkambi-experienced Population Who Are Homozygous for the F508del-CFTR Mutation VX16-661-114

Dates: OCT2017 - 09OCT2018

Funds earned: $11,459.65

Number of patients enrolled and completed: 3 enrolled, 3 completed

Funding Source: pharmaceutical industry funded

Project Number: 6123817700

Role: PI

A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated With Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors (The CF-FC Study)

Dates: OCT2016 – MAR2017

Funds earned: N/A

Number of patients enrolled and completed: N/A, terminated by sponsor prior to enrollment

Funding Source: pharmaceutical industry funded

Project Number: pending

Role: PI

An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects with Pulmonary Arterial Hypertension Currently Using Tyvaso (TIP-PH-101)

Dates: NOV2019 - ongoing

Funds earned: $134.623.08

Number of patients enrolled and completed: 5 enrolled, study ongoing

Funding Source: pharmaceutical industry funded

Project Number: 6123821500

Role: Sub-I

A phase 1B/2A Multi-center, double-blind, randomized, placebo-controlled, single and multiple ascending dose study to evaluate the safety and tolerability of AP-PA02 Multiple Phage Therapeutic candidate for inhalation in subjects with cystic fibrosis and chronic pulmonary pseudomonas aeruginosa (PA) infection (Armata AP-PA02-101)

Dates: APR2021 - ongoing

Funds earned: $25,575

Number of patients enrolled and completed: 2 enrolled, study ongoing

Funding Source: pharmaceutical industry funded

Project Number: 6123829400

Role: Sub-I

A master protocol to test the impact of discontinuing chronic therapies in people with cystic fibrosis on highly effective CFTR modulator therapy (Simplify-19)

Dates: APR2021 - ongoing

Funds earned: pending

Number of patients enrolled and completed: 8 enrolled, study going

Funding Source: Cystic Fibrosis TDN

Project Number: 61238329

Role: Sub-I

Published Bibliography

Peer Reviewed

S Gangi, F Saidi, KN Patel, D Shine. Cardiovascular complications after GI endoscopy: Occurrence and risks in a large hospital system. Gastrointestinal Endoscopy 2004, 60:679-685

KN Patel, KD Ganatra, JH Bates, MP Young. Variation in the rapid shallow breathing index associated with common measurement techniques and conditions. Respiratory Care 2009, 54(11):1462-1466

I Vlaminck, L Martin, M Kertesz, K Patel, M Kowarsky, C Strehl, G Cohen, H Luikart, N Neff, J Okamoto, M Nicolls, D Cornfield, D Weill, H Valantine, K Khush, S Quake. Non-invasive monitoring of infection and rejection after lung transplantation. Proc Natl Acad Sci 2015, 112(43):13336-13341

JJ Mooney, H Hedlin, P Mohabir, R Vazquez, J Nguyen, R Ha, P Chiu, K Patel, MR Zamora, D Weill, MR Nicolls, GS Dhillon. Lung Quality and Utilization in Controlled Donation After Circulatory Determination of Death Within the United States. Am J Transplant. 2016, 16(4):1207-1215

RL Yang, AW Kurian, LM Winton, D Weill, K Patel, K Kingham, IL Wapnir. Addressing inherited predisposition for breast cancer in transplant recipients. J Surg Oncol 2016, 113(6):605-608

Pasupneti S, Patel K, Mooney JJ, Chhatwani L, Dhillon G, Weill D. Lung Transplantation following death by drowning: a review of the current literature. Clin Transplant. 2016, 30(10):1195-1197

Agbor-Enoh S, Wang Y, Tunc I, Jang MK, Davis A, De Vlaminck I, Luikart H, Shah PD, Timofte I, Brown AW, Marishta A, Bhatti K, Gorham S, Fideli U, Wylie J, Grimm D, Goodwin N, Yang Y, Patel K, Zhu J, Iacono A, Orens JB, Nathan SD, Marboe C, Berry GJ, Quake SR, Khush K, Valantine HA. Donor-derived cell free DNA predicts allograft failure and mortality after lung transplantation. EbioMedicine. 2019, 40:541-553

Sharma NS, Vestal G, Wille K, Patel KN, Cheng F, Tipparaju S, Tousif S, Banday MM, Xu X, Wilson L, Nair VS, Morrow C, Hayes D, Seyfang A, Barnes S, Deshane JS, Gaggar A. Differences in Airway Microbiome and Metabolome of Single Lung Transplant Recipients. Respir Res. 2020, 21(1):104

Sethi J, Bugajski A, Patel KN, Davis NM, Willie KM, Qureshi MR, Banday MM, Lin M, Emani V, Weill D, Tumin D, Hayes D, Sharma NS. Recipient Age Impacts Long-Term Survival in Adult Cystic Fibrosis Subjects after Lung Transplantation. Ann Am Thorac Soc. 2021, 18(1):44-50

Banday MM, Kumar A, Vestal G, Sethi J, Patel KN, O’Neill EB, Finan J, Cheng F, Lin M, Davis NM, Goldberg H, Coppolino A, Mallidi HR, Dunning J, Visner G, Gagger A, Seyfang A, Sharma NS. N- myc-Interactor Mediates Microbiome Induced Epithelial to Mesenchymal Transition and is Associated with CLAD. J Heart Lung Transplant. 2021, 40(6):447-457

Fukumoto J, Lin M, Banday MM, Patil SS, Krishnamurthy S, Breitzig M, Soundararajan R, Galam L, Narala VR, Johns C, Patel K, Dunning J, Lockey RF, Sharma NS, Kolliputi N. Aberrant Expression of ACO1 in Vasculatures Parallels Progression of Idiopathic Pulmonary Fibrosis. Front. Pharmacol. 2022 (on-line)

Smirnova, NF, Riemondy K, Bueno M, Collins S, Surech P, Wang XA, Patel KN, Cool C, Konigshoff M, Sharma NS, Eickelberg O. Single-cell transciptome mapping identifies a local, innate B cell population driving chronic rejection after lung transplantation. JCI Insight. 2022, 7(17):e156648

Bandy MM, Rao SB, Shankar S, Khanday MA, Finan J, O’Neill E, Coppolino A, Seyfang A, Kumar A, Rinewalt DE, Goldberg HJ, Woolley A, Mallidi HR, Visner G, Gaggar A, Patel KN, Sharma NS. IL-33 mediates Pseudomonas induced airway fibrogenesis and is associated with CLAD. J Heart Lung Transplant. 2023. 42(1):53-63

Smith JE, Amariei DA, Herazo-Maya J, Niyazi S, Ruffalo RF, Patel KN, Qureshi MR, Abraham J, Bandyopadhyay D. Chronic Pulmonary Silicone Embolism Syndrome Following Saline Breast Implants. AIM Clinical Cases November 2023

Tourki B, Jia M, Karampitsakos T, Vera I, Arsenault A, Marlin K, Perrot C, Farsaei F, Allen D, Rutenberg D, Bandyopadhyay D, Restrepo R, Qureshi M, Patel K, Tzouveleki A, Kapetanaki M, Guardela J, Kim K, Benos P, Herazo-Maya J. Single-cell transcriptomics discriminates the course of COVID-19 and Idiopathic Pulmonary Fibrosis. eBioMedicine (pending)

Parket J, Doyle WN, Peddi P, Stevens M, Rogers M, Mhaskar R, Patel K, Ducoin C. Postoperative outcomes of antireflux surgery in lung transplant recipients. J Gastrointest Surg. 2025, 29(9):102126

Case Reports, Technical Notes, Letters

D Weill, K Patel. Lung Transplant for Cystic Fibrosis. Curr Respir Care Rep. 2013, 2:180-186.

Book, Textbooks, Chapters

PE Parsons, KN Patel. Acute Respiratory Distress Syndrome. In: Critical Care Secrets, 4^th Edition, ed. PE Parsons & JP Wiener-Kronish. Elsevier, Philadelphia, PA, 2007, pp. 142-146.

B Suratt, KN Patel. Organ Donation. In: Critical Care Secrets, 5^th Edition, ed. PE Parsons & JP Wiener-Kronish. Elsevier, Philadelphia PA, 2013, pp. 588-592.

B Suratt, K Patel. Organ Donation. In: Critical Care Secrets, 6^th Edition, ed. PE Parsons, JP Wiener-Kronish, RD Stapleton & L Berra. Elsevier, Philadelphia, PA, 2019, pp. 446-453.

K Patel, D Weill. History of Lung Transplantation. In: Psychosocial Care of End-Stage Organ Disease and Transplant Patients, ed. Y Sher & JR Maldonado. Springer, Cham, Switzerland, 2019, pp. 273-277.

K Patel, J Hupp, L Dichiara, N Davis, P Patel. What is involved in Lung Transplantation? In: Facing Organ Transplantation: A Guide for Patients and their Families, ed. Y Sher & T Stern. MGH Psychiatry Academy, 2020, pp. 97-104.

Abstracts Presentations

KN Patel, KD Ganatra, JH Bates, MP Young. Variation in the rapid shallow breathing index associated with common measurement techniques and conditions. American Thoracic Society International Conference 2006

E Riesenfeld, KN Patel, MP Young, JH Bates. Informed Consent in the Intensive Care Unit. American Thoracic Society International Conference 2007

Mooney JJ, Hedlin H, Mohabir PK, Guillamet RV, Ha R, Chiu P, Patel K, Weill D, Nicolls MR, Dhillon GS. Donation after Circulatory Determination of Death Donor Characteristics and Lung Donor Utilization within the United States. International Society for Heart and Lung Transplantation 2015

Mooney JJ, Hedlin H, Mohabir PK, Guillamet RV, Ha R, Chiu P, Patel K, Weill D, Nicolls MR, Dhillon GS. Recipient Outcomes in Donation after Circulatory Determination of Death Lung Donors Within the United States. International Society for Heart and Lung Transplantation 2015

S Pasupneti, A Lawrence, L Chhatwani, K Patel, R Ha, J Boyd, G Dhillon, J Mooney. Combined Lung-Liver Transplantation: The United States Experience. International Society of Heart and Lung Transplantation 2016

Sharma NS, Wille KM, Patel K, Pachinbuvaran M, Weill D, Deshane J. Airway Microbiome and Metabolome differentiates Native from Allograft Lung in Single Lung Transplant Recipients. International Society of Heart and Lung Transplantation 2018

J Sethi, GA Garrido Rosa, K Patel, N Sharma. Predicting Long Term Survival in Lung Transplant: Analysis of United Network for Organ Sharing (UNOS) Database. International Society of Heart and Lung Transplantation 2019

J Sullivan, N Sharma, K Patel, A Logan. Analysis of Risk Factors for Invasive Mold Infections in Lung Transplant Recipients. International Society of Heart and Lung Transplantation 2019

B Tourki, I Vera, C Perrot, F Farsaei, A Arsenault, B Juan-Guardela, D Allen, R Restrepo, D Bandyopadhyay, E Belli, G Katlaps, K Patel, S Liggett, K Kim, J Herazo-Maya. Peripheral Blood Gene Expression Changes Predicts Mortality and Treatment Response in Acute COVID-19 and Associate with Lung Fibrosis. American Thoracic Society International Conference 2022

Society Memberships

American Thoracic Society 2005 - present

International Society for Heart and Lung Transplantation 2008 - present

Ad hoc Reviewer, Manuscripts

Respiratory Medicine

OBM Transplantation

The Journal of Heart and Lung Transplantation

Biomolecules

European Respiratory Journal (Open Research)

Meet Your Healthcare Provider